Hookipa Pharma Inc (NASDAQ:HOOK – Free Report) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Hookipa Pharma in a report issued on Friday, April 26th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($0.17) for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Hookipa Pharma’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Hookipa Pharma’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.19) EPS.
Separately, Royal Bank of Canada reissued an “outperform” rating and set a $5.00 price objective on shares of Hookipa Pharma in a report on Monday, March 25th.
Hookipa Pharma Trading Up 5.3 %
NASDAQ HOOK opened at $0.94 on Monday. Hookipa Pharma has a 1 year low of $0.41 and a 1 year high of $2.05. The firm has a market capitalization of $93.11 million, a price-to-earnings ratio of -1.07 and a beta of 1.02. The firm’s 50 day simple moving average is $0.75 and its 200 day simple moving average is $0.66.
Hookipa Pharma (NASDAQ:HOOK – Get Free Report) last announced its earnings results on Friday, March 22nd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. The firm had revenue of $7.41 million for the quarter, compared to analyst estimates of $3.60 million. Hookipa Pharma had a negative net margin of 405.28% and a negative return on equity of 72.30%.
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Featured Articles
- Five stocks we like better than Hookipa Pharma
- Do ETFs Pay Dividends? What You Need to Know
- The 3 Hottest Insiders Buys This Month
- What Are the FAANG Stocks and Are They Good Investments?
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- What is the Shanghai Stock Exchange Composite Index?
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
